Goals of work Multiple sites enable more successful completion of adequately powered phase III studies in palliative care. Audits of the frequency and distribution of the symptoms of interest can better inform research planning by determining realistic recruitment goals for each site. The proposed studies are to improve the evidence-base for registration and subsidy applications for frequently encountered symptoms where current pharmacological interventions are being used 'off-licence'. Methods Six services participated in a standardised, retrospective, consecutive cohort audit of five symptoms of their inpatient populations to inform the design of double blind randomised controlled phase III studies to which each site would recruit simultaneously. The audit covered all deaths in a 3-month period for people who were referred to a specialist palliative care service who had at least one inpatient admission between referral and death, regardless of when the person was referred to the service. The audits were based around inclusion and exclusion criteria for the proposed studies. Main results Of the 468 people whose medical records were reviewed, potential study participant rates varied by symptom having accounted for general and specific inclusion and exclusion criteria: pain 17.7%; delirium 5.8%; anorexia 5.1%; bowel obstruction 2.8% and cholestatic itch 0%. For those people with a symptom of interest, it was noted at the beginning of the inpatient admission more than half the time. Of all inpatients, fewer than one third would be eligible to participate in at least one study. Conclusions These data provide a baseline estimate of potential people to approach about clinical trials in supportive care but do not account for clinician 'gatekeeping', lack of interest in participating nor withdrawal from the study once initiated. The data are retrospective and therefore, limited by clinical documentation. The audit directly informed an increase in the number of participating sites.
Introduction
Large scale trials in supportive, palliative, and hospice care are feasible, especially if protocols can be designed appropriately for use in several sites simultaneously [1] . One reason for the failure of many studies in palliative care is an over-estimation of likely recruitment even for frequently encountered symptoms. A more comprehensive understanding of patterns of symptom occurrence for each participating site (given local variations in referral patterns) and general factors that may affect potential phase III study participation in a supportive and palliative care population need to be included in feasibility assessment. The design needs to take careful account of such findings if studies are going to be successful, and key performance indicators for each site can be tailored to local symptom patterns to monitor trial progress.
Rigorous phase III studies need to be undertaken to widen existing medication registration criteria (clinical indication, target population, formulation, route of administration) and to demonstrate cost-effectiveness for subsidy applications in supportive and palliative care. The Australian Government has provided funds for a national multi-site Palliative Care Clinical Studies research Collaborative (PaCCSC) to undertake a series of phase III studies to improve the evidence-base for the use of key symptom control medications and evaluate their cost-effectiveness across the community. [2] The medications chosen in this process defined the symptoms that are audited in this report. There is an expectation that PaCCSC will also be a catalyst for capacity building to improve clinical research capability in supportive and palliative care nationally and improve the way cost-effectiveness is analysed in this population. All the studies have been designed to meet CONSORT guidelines [3] and achieve the highest possible Jadad scores [4] while also using standardised toxicity reporting (National Cancer Institute common terminology criteria) and measurement tools validated in the study population for primary end points [5] .
The PaCCSC collaborative research team encompasses key skills in supportive and palliative care clinical trials research, clinical pharmacology, pharmaco-economics, biostatistics and drug regulatory affairs. The research team is overseen by a national Management Advisory Board and supported by a Scientific Committee providing an internal peer review process for trial development. A Trial Management Committee with representatives from each trial and each participating site oversees the development and execution of individual studies.
Participating sites represent the diversity of models of supportive and palliative care service provision in metropolitan Australia. PaCCSC sites vary in terms of size, sources of referrals, resources and the local clinical team's experience with and attitudes towards clinical trials. This variety of service settings helps to optimise the generalisability of any subsequent findings [6] but may limit the ability of each site to recruit to each study at the same rate.
Audit methodology has been used by researchers in other disciplines conducting multi-site studies to determine a site's ability to recruit to specific studies [7] . The aim of this paper is to describe a multi-site, retrospective consecutive cohort feasibility audit of five symptoms of interest and its implications for the phase III randomised controlled trials that will be run subsequently.
Patients and methods
Development of the audit The audit was developed to determine the frequency with which symptoms of interest occurred in the clinical services and the likely proportion of people who would meet general and study-specific eligibility criteria for the proposed phase III studies. Symptom frequencies were sought for complex pain (that has not responded to appropriate combination therapy), anorexia, acute confusion/delirium, malignant bowel obstruction and cholestatic itch. The audit was developed from draft protocols for each phase III study under consideration by clinical trialists, a research statistician, health economist and a clinical pharmacist.
Study setting
Six specialist palliative care services drawn from all mainland states of Australia were involved, having competed for participation in PaCCSC. These sites had demonstrated experience in randomised controlled trials and were a combination of 'consultation only' teaching hospital services (n=1), regional services encompassing inpatient, outpatient and community services (n=3) and those with inpatient and consult services (n=2). All sites for the audit were metropol-itan services with people with cancer as the predominant referral source (Table 1) .
Participants A consecutive cohort of all people who died within a 3-month period (where the most recent death was at least 6 months before the audit to allow time for the collation of all relevant medical records) and had at least one inpatient admission between referral and death (as studies were to be for inpatients only) was generated by each of the six PaCCSC sites (Fig. 1) . The inpatient admission needed to have formally involved the supportive and palliative care service (either as direct care, shared care or consultative input). The audit did not include people only referred for community support who were not admitted to hospital between referral and death.
Data collection The retrospective chart review of clinical care data was conducted in the second half of 2007. A project officer with an appropriate health-related background was employed for 3 months to conduct the audit at each site. From the medical records of the service (inpatient, outpatient and community care) and the health services through which care was provided, patient demographics, primary diagnosis, reasons for referral to the specialist palliative service, reasons for admission to an inpatient unit (where the first admission after referral to the specialist palliative care service was used for data collection), functional status, prevalence of symptoms and medication use during the first hospital admission were recorded. Data, both at the time of and during the course of this admission, were captured in the audit. Data were collected from routine clinical records with services using a variety of ways of capturing data, none of which was the same between the participating services.
A comprehensive data collection guide and glossary were developed to ensure consistent coding across all sites.
Training and support was provided nationally to assist the project officers coding and entering the data. Key definitional issues included prevalent symptoms (those present on admission to the inpatient unit), incident symptoms (those symptoms that occurred or recurred during the person's inpatient stay) and the distinction between general criteria for inclusion/exclusion (those common to all studies and related to global abilities to participate in clinical trials) and those specific to individual studies (Table 4) .
Data management Data were recorded on paper-based case report forms and then entered electronically onto a password protected, web-based access database (www.caresearch.com. au). Each new record with completed data uploaded on the web system generated an automatic email to the coordinating site to enable real time checking of data against copied source records before the new file was merged into the master database. As expected, there were missing data, and these fields in the audit were left blank.
Ethics approval The symptom audit was deemed a quality assurance exercise by the sites' respective Human Research Ethics Committees (HREC). All data were de-identified and aggregated for each site. Permission was granted by all HRECs to publish the outcomes of the audit.
Results

Characteristics of potential participants
A total of 468 deaths occurred in the six services in a 3-months period where the deceased had at least one admission to an inpatient unit between referral and death ( Table 1) . Of these people, 66% were male, and 54% were The number of inpatient admissions for participating services each month ranged from 15 to 92 people. The main sources of referral for the services were for people already hospitalised. The most frequently encountered diagnosis was lung cancer (Table 2) and pain, dyspnoea, nausea and vomiting; and caregiver needs were the most frequently cited reasons for referral to the services.
Two hundred and thirty two (50%) people had performance status recorded in four sites. The Eastern Cooperative Group (ECOG) measure was used in 144 cases and the Australian-modified Karnofsky Performance Scale (AKPS) in 88. Overall performance status was poor with 75%, having an AKPS of 50 or less or 72%, an ECOG score of 2 or greater.
Evaluation of symptoms
Both the prevalence of symptoms on admission and the incidence of that symptom occurring for the first time or reoccurring during the admission were coded. Between 50% and 91% of all occurrences of a symptom of interest were present on admission to the inpatient unit (Table 3) .
Eligibility factors
All general and study-specific reasons for trial eligibility and ineligibility are outlined in Table 4 .
Frequency of a person qualifying for a study Individual studies had potential participation rates varying between 0% (cholestatic itch) and 62% (malignant bowel obstruction) if the symptom was present either on or during an admission (Table 3) . Of the 468 people whose medical records were reviewed, potential study participant rates varied by symptom having accounted for general and specific inclusion and exclusion criteria: pain 17.7%; delirium 5.8%; anorexia 5.1%; bowel obstruction 2.8% and cholestatic itch 0%. (Table 3 ) Of the 468 people with a palliative diagnosis who had their clinical records examined, a total of 134 (29%) would have met eligibility criteria. Of these people, 117 (88%) would have qualified for one study, 16 (12%) for two studies and 1 (1%) for three or more of the proposed studies.
Discussion
There is a continuing ethical imperative to improve the clinical evidence for quality supportive and palliative care in areas that are of relevance to patients and their caregivers [8] . This audit, in preparing for a series of adequately powered phase III studies with embedded patient-defined clinical outcomes and cost-effectiveness analyses, provides a unique basis for estimating the population of potential participants. Such research aims to improve the quality of care by measuring the net clinical effect of pharmacological interventions in clinical presentations in supportive and palliative care incorporating the benefits and toxicities. As each of the medications being studied through PaCCSC is out of patent, public funding is an appropriate way to do this research. To achieve such an ambitious programme of work, trial design needs to be informed by as much information in the planning stage as possible.
What data are supported by the current study?
This audit provided a snapshot of the patient population in a number of inpatient clinical settings around Australia and found that 29% of people were potentially eligible to participate in the target clinical studies. The total symptom prevalence patterns (including those symptoms prevalent on inpatient admission and those that developed or recurred during the inpatient stay) were similar to that of other audits conducted in supportive and palliative care [9] . A systematic review of symptom prevalence in the last weeks of life Admissions to inpatient units P a t i e n t s Time Fig. 1 Illustrative figure of admissions to and death whilst being supported by a specialised palliative care service in relation to the audit of potential trial participants. Admission to inpatient unit is noted separately. All deaths within a 3-month period became the basis of the audit, irrespective of when a person was referred to the service found that five symptoms, (fatigue, pain, lack of energy, weakness and anorexia) occurred in more than 50% of all people [10] . The findings are also consistent with the data on the reasons that referral to specialised supportive and palliative care services occurs [11] . The clinical conditions being studied fit into two general categories-those that can occur consistently with advanced disease often presenting with an insidious onset where prevalence is crucial (pain, anorexia) and those that are less likely to occur but often precipitate unexpected changes in care where incidence is more important (delirium, bowel obstruction). Both general criteria (inability to complete study questionnaires, poor cognition, and poor performance status) and specific inclusion and exclusion criteria for each symptom were evaluated in the audit.
Given that 12% of potentially eligible people could theoretically participate in two or more studies, there is the need to understand from the data in this audit which studies are likely to have the most difficulty recruiting. It is important to prioritise participation in studies where enrollment rates are likely to be lower.
There are a number of factors in the literature that will affect the participation in supportive and palliative care clinical studies that cannot be estimated from the audit. These include reasons that people do not want to participate in any study [12, 13] and clinicians who will not refer an apparently eligible person to study staff [14, 15] . Other factors such as staff enthusiasm and the underlying (lack of) research culture for each participating clinical unit will be of relevance to final participation rates.
Monitoring of trials will need to consider key performance indicators including the rates at which and reasons people decline to participate in the study, withdraw from a study between consent and randomization or between randomization and completion [16] [17] [18] . These considerations will influence recruitment and retention strategies. Although in these studies it is not expected that there will be high rates of withdrawal as a consequence of the study itself, there will be people who withdraw as they become too frail to continue participation.
The studies have been designed as effectiveness studies including the widest possible group of participants (in contrast to a highly selected sub-population in an efficacy study). Despite this, up to 28% of people referred to the services with a symptom of interest are not even likely to meet general eligibility criteria. The majority of people are unable to participate because of the very poor functional status, which is also reflected in the relatively low discharge rate back to the community in some of the participating inpatient units.
Direct modifications to study design/conduct as a result of the audit Given the complexity of running a multi-site study in any population, it is important that each site understands the performance criteria for its continued participation in the collaborative. This audit has helped to set realistic goals for each study in each site by establishing the baseline practice in which the studies will be conducted. As some of the variations between sites can be explained by the referraldependent nature of supportive and palliative care, key performance indicators tailored to each site based on its referral patterns have resulted from the audit.
Study design was refined as a result of the audit by:
-defining two studies that would need more recruiting sites to meet timelines; -identifying objectively sites that would be unable to recruit effectively to one or more studies; -identifying that some studies are likely to accrue participants more slowly, requiring protocols to ensure every single potential participant is identified systematically and -changing the studies from running sequentially to simultaneously given the small numbers of potential participants who had more than one symptom of interest. Does not include specific assessment of the Memorial Delirium Assessment score nor the Nursing Delirium Assessment scores as these were not routinely collected in any of the participating sites before the study c Excludes vomiting Table 4 General and study-specific inclusion and exclusion criteria for clinical studies A crucial finding that is still to be fully implemented in each site is that in more than one in two people, the symptom of interest was present at the time of admission to the inpatient unit ( Table 3 ). As such, adequate screening at admission for eligibility becomes an imperative process to institute.
Other collateral benefits of the audit It is difficult to bring together palliative clinicians, researchers and policy makers for such an ambitious programme of research, especially when some of the researchers had been competitors for very limited palliative care research funds in the recent past. The audit allowed the committee structure of the collaborative to establish its processes away from the pressure of the actual clinical studies. The audit provided an opportunity for each site to start to work collaboratively with the national coordinating centre and to finalise and test the standard operating procedures and online data entry systems. It also allowed the national coordinating centre to start working with each site, its research ethics committee and their clinicians.
The audit allowed the inclusion and exclusion criteria of each study to be critically tested and refined in the light of the clinical settings in which the studies are being conducted. The audit also encouraged sites to identify and engage with other clinical units in their institutions whose patients could be eligible for the studies.
Limitations-methods
As with any retrospective chart review, there are significant limitations as they only allow information that has been recorded to be collected [19] . The audit highlighted the lack of documentation of key data variables of interest. For example, only one half of the people had functional status recorded in their clinical records despite this being a patient-valued metric, and a surprisingly small proportion of patients had anorexia documented. These data elements are now included in a national benchmarking project, which is collecting point of care data on more than 75% of all people referred to specialised supportive and palliative care services nationally at point of clinical contact [20] .This should lead to better levels of comparable documentation fields in the future.
The symptom of greatest concern was delirium. Most units had no routine screening processes despite its prevalence in cancer care [21] . The tools that will be used in the studies (which could be reasonably used in clinical practise) will be the Memorial Delirium Assessment Scale [22] and the Nursing Delirium Screening scale [23] .
The study chose to use deaths and retrospectively assess for study eligibility from the first inpatient admission after referral to the palliative care service (Table 3 ). This ensured the best possible longitudinal data for study eligibility at any time after admission. Because only one inpatient admission was used for each participant, this may systematically underestimate the overall incidence of symptoms of interest given that they may develop at any time along the disease trajectory. New inpatient admissions could equally have been the point at which data collection started, but for an audit, this would have been more resource intensive without increasing the detail or quality of the data collected.
Limitations-sample
The most obvious limitation in the sample is that it did not include patients for whom the supportive and palliative care service was being consulted in the community. At least one of the studies (malignant bowel obstruction) will now enrol participants in the community if their symptoms are uncontrolled. None of the services involved has any particular local relationships or referral patterns that differ markedly from the general patterns of referral other than one service that has very limited after hours capacity for surgery, potentially limiting the likelihood of recruiting to the study on bowel obstruction.
Implications for palliative care research more generally
The most important findings from this audit are that it has helped to foster a new collaborative, allowed expansion of site numbers for specific studies and refinement of trial design in order to optimise successful outcomes for the phase III studies. These issues will be judged ultimately by successful completion of the definitive studies.
